The Apex compound guide
Begin with a research question. Then review the molecular pathway, compare the published evidence, and keep its limits visible.
Explore the research guide
Browse every profile, or focus the collection by molecular pathway, signaling system, or experimental model.
Researchers use this inhibitor to examine NNMT activity, nicotinamide metabolism, methyl-donor chemistry, and adipocyte models. Published intervention evidence remains preclinical.
AOD-9604 was developed to isolate selected lipid-metabolism questions from full growth-hormone signaling. Larger clinical research did not meet its primary endpoint.
APX-2 is the catalog name for tirzepatide (LY3298176), a peptide that engages two incretin receptors: GIPR and GLP-1R.
Research examines coordinated GLP-1, GIP, and glucagon receptor activity. Published clinical findings are formulation- and study-specific, and APX-3 remains investigational.
ARA-290, also called cibinetide, is an 11-amino-acid peptide modeled on part of erythropoietin. It is studied in cellular injury and small-nerve-fiber research.
Research examines vascular signaling, nitric-oxide pathways, inflammatory signaling, and tissue-response models. The evidence base remains predominantly preclinical.
The combination is studied across vascular signaling, actin biology, cell migration, and tissue-response models. The evidence base is largely laboratory and animal research.
The blend provides two experimental inputs into growth-hormone and IGF-1 signaling. Component-level observations do not establish the behavior, safety, or efficacy of the fixed research blend.
Research has examined sleep-related EEG activity, neuroendocrine signaling, and stress models. The published clinical record is old, small, and inconsistent.
Research explores telomerase expression, telomere biology, cell-aging models, and neuroendocrine signaling. Cell-culture observations do not establish organism-level outcomes.
Research examines copper-dependent signaling, fibroblast activity, extracellular-matrix turnover, and cell migration. Findings are limited and highly formulation-specific.
GLOW BLEND combines nominal amounts of BPC-157, GHK-Cu, and TB-500 in one research material. Component-level observations do not establish the behavior, safety, or efficacy of the fixed blend.
Glutathione is studied as a cellular redox buffer across peroxide metabolism, detoxification enzymes, and protein-thiol regulation. Intervention findings are mixed and formulation-specific.
Researchers use IGF-1 LR3 to examine IGF-1 receptor activity, cell growth, differentiation, and binding-protein interactions. Controlled clinical efficacy has not been established.
Kisspeptin-10 is a short peptide form derived from the KISS1 precursor. Its receptor, KISS1R (also called GPR54), is studied in neuroendocrine signaling.
KPV is the Lys-Pro-Val tripeptide. This catalog entry identifies its sequence, molecular reference, and nominal size without making a therapeutic or human-use claim.
Research centers on metabolic stress, AMPK-linked pathways, and communication between mitochondria and the nucleus. Translation beyond preclinical models remains uncertain.
NAD+ is studied across redox reactions, mitochondrial energetics, DNA-repair enzymes, and cellular signaling. Direct intervention evidence remains limited.
Pinealon is the research name for the tripeptide Glu–Asp–Arg, abbreviated EDR. The selected studies examine oxidative stress in cells and a specific rat developmental-stress model.
Researchers study melanocortin receptors, central nervous system pathways, and behavioral endpoints. Evidence for an approved formulation does not transfer to a separate research material.
Research centers on GABA-related pathways, neuropeptide regulation, and behavioral stress models. Published clinical reports are small and have limited independent replication.
Research examines neurotrophin expression, neural stress models, and related signaling pathways. Much of the evidence is preclinical or not broadly replicated.
Researchers examine cardiolipin binding, mitochondrial membrane organization, respiratory-chain activity, and oxidative-stress responses. Clinical findings remain condition-specific and mixed.
Researchers use tesamorelin to examine GHRH receptor activity, growth-hormone signaling, IGF-1, and adipose-tissue biology. Evidence from an approved formulation cannot be transferred to a separate research material.
Research focuses on T-cell biology, innate immune sensing, Toll-like receptors, and cytokine signaling. Clinical findings vary by condition and study design.
VIP is a 28-residue peptide also indexed as vasoactive intestinal peptide and aviptadil. This catalog entry presents its molecular reference and nominal size without making a therapeutic or human-use claim.
Inside every compound guide
Each profile follows the same four-step path so you can move from the research target to the source record and its limits without losing your place.
Return to the compound indexIdentify the molecular target, signaling system, or experimental model that makes the material relevant to a research plan.
Follow the material from its target through the receptors, enzymes, and intracellular signals under investigation.
Separate cell and animal observations from clinical findings, and note which formulation and study design produced each result.
Mark unanswered questions, unreplicated findings, and conclusions that the available evidence cannot support.
A pathway observation is not proof of safety, efficacy, or suitability for personal use. The guide does not provide dosing, administration, or personal-use instructions.
